Skip to main content

Rockwell Medical Value Stock - Dividend - Research Selection

Rockwell medical

ISIN: US7743741024 , WKN: 916118

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Rockwell Medical, Inc. operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company\'s lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment. It also provides Calcitriol, a generic active vitamin D injection, which is indicated for the treatment of secondary hyperparathyroidism in dialysis patients. In addition, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, Renalpure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubings, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Its concentrated dialysate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient\'s bloodstream. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. The company\'s target customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and technical and purchasing personnel. Rockwell Medical, Inc. was founded in 1995 and is based in Wixom, Michigan.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Rockwell Medical Inc (RMTI) Q1 2025 Earnings Call Highlights: Navigating Challenges and ...

2025-05-13
Despite a decline in net sales, Rockwell Medical Inc (RMTI) remains optimistic with strategic expansions and new product launches.

Q1 2025 Rockwell Medical Inc Earnings Call

2025-05-13
Q1 2025 Rockwell Medical Inc Earnings Call

Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates

2025-05-12
Rockwell Medical (RMTI) delivered earnings and revenue surprises of -33.33% and 6.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Rockwell Medical: Q1 Earnings Snapshot

2025-05-12
RMTI) on Monday reported a loss of $1.5 million in its first quarter. The Wixom, Michigan-based company said it had a loss of 4 cents per share. The maker of products used in the treatment of kidney disease and anemia posted revenue of $18.9 million in the period.

Rockwell Medical, Inc. (RMTI) Q1 2025 Earnings Call Transcript

2025-05-12
Rockwell Medical, Inc. (NASDAQ:RMTI) Q1 2025 Earnings Conference Call May 12, 2025 8:00 AM ETCompany ParticipantsHeather Hunter - SVP, Chief Corporate...

Rockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025

2025-04-14
WIXOM, Mich., April 14, 2025--Rockwell Medical will release its results for the first quarter ended March 31, 2025 on Monday, May 12, 2025.

Why Rockwell Medical Inc. (RMTI) Went Down On Thursday?

2025-03-21
We recently published a list of Thursday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where Rockwell Medical Inc. (NASDAQ:RMTI) stands against other Thursday’s worst-performing stocks. Wall Street’s main indices edged lower on Thursday, erasing gains from the previous trading day that was buoyed by the Federal Reserve’s decision […]

Rockwell Medical, Inc. (NASDAQ:RMTI) Shares Could Be 36% Below Their Intrinsic Value Estimate

2025-03-21
Key Insights The projected fair value for Rockwell Medical is US$2.18 based on 2 Stage Free Cash Flow to Equity...

Rockwell Medical Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

2025-03-21
Rockwell Medical ( NASDAQ:RMTI ) Full Year 2024 Results Key Financial Results Revenue: US$101.5m (up 21% from FY 2023...

Rockwell Medical Inc (RMTI) Q4 2024 Earnings Call Highlights: Strong Sales Growth Amidst ...

2025-03-21
Rockwell Medical Inc (RMTI) reports significant sales growth and improved profitability, while navigating a major customer transition impacting 2025 projections.